373 related articles for article (PubMed ID: 35700773)
21. CXCL1-CXCR2 signalling mediates hypertensive retinopathy by inducing macrophage infiltration.
Wang S; Bai J; Zhang YL; Lin QY; Han X; Qu WK; Zhang PF; Ge YS; Zhao Q; Li HH
Redox Biol; 2022 Oct; 56():102438. PubMed ID: 35981418
[TBL] [Abstract][Full Text] [Related]
22. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Peng W; Li J; Chen R; Gu Q; Yang P; Qian W; Ji D; Wang Q; Zhang Z; Tang J; Sun Y
J Exp Clin Cancer Res; 2019 Sep; 38(1):393. PubMed ID: 31492150
[TBL] [Abstract][Full Text] [Related]
23. Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity.
Chen L; Gu J; Qian Y; Li M; Qian Y; Xu M; Li J; Wen Y; Xia L; Li J; Xia Q; Kong X; Wu H
Cell Mol Gastroenterol Hepatol; 2019; 7(3):623-639. PubMed ID: 30630119
[TBL] [Abstract][Full Text] [Related]
24. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
[No Abstract] [Full Text] [Related]
25. CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration.
Wang L; Zhang YL; Lin QY; Liu Y; Guan XM; Ma XL; Cao HJ; Liu Y; Bai J; Xia YL; Du J; Li HH
Eur Heart J; 2018 May; 39(20):1818-1831. PubMed ID: 29514257
[TBL] [Abstract][Full Text] [Related]
26. Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis.
Li YM; Liu ZY; Wang JC; Yu JM; Li ZC; Yang HJ; Tang J; Chen ZN
Hepatology; 2019 Nov; 70(5):1564-1581. PubMed ID: 31021443
[TBL] [Abstract][Full Text] [Related]
27. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
Yi J; Peng F; Zhao J; Gong X
Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
[TBL] [Abstract][Full Text] [Related]
28. METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner.
Yu T; Liu J; Wang Y; Chen W; Liu Z; Zhu L; Zhu W
Biochem Biophys Res Commun; 2022 Jul; 614():9-16. PubMed ID: 35567945
[TBL] [Abstract][Full Text] [Related]
29. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
Zhou D; Tang W; Xu Y; Xu Y; Xu B; Fu S; Wang Y; Chen F; Chen Y; Han Y; Wang G
Mol Oncol; 2021 Aug; 15(8):2172-2184. PubMed ID: 33411363
[TBL] [Abstract][Full Text] [Related]
30. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
31. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.
Pan Y; Chen H; Zhang X; Liu W; Ding Y; Huang D; Zhai J; Wei W; Wen J; Chen D; Zhou Y; Liang C; Wong N; Man K; Cheung AH; Wong CC; Yu J
Cell Rep Med; 2023 Aug; 4(8):101144. PubMed ID: 37586322
[TBL] [Abstract][Full Text] [Related]
32. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
34. ALKBH1-mediated m
Chen W; Wang H; Mi S; Shao L; Xu Z; Xue M
Mol Oncol; 2023 Feb; 17(2):344-364. PubMed ID: 36550779
[TBL] [Abstract][Full Text] [Related]
35. CXCR2-Mediated Granulocytic Myeloid-Derived Suppressor Cells' Functional Characterization and Their Role in Maternal Fetal Interface.
Kang X; Zhang X; Liu Z; Xu H; Wang T; He L; Zhao A
DNA Cell Biol; 2016 Jul; 35(7):358-65. PubMed ID: 27027573
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response.
Liu P; Li X; Lv W; Xu Z
Biomed Pharmacother; 2020 Feb; 122():109693. PubMed ID: 31812015
[TBL] [Abstract][Full Text] [Related]
37. A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis.
Zhou Z; Xia G; Xiang Z; Liu M; Wei Z; Yan J; Chen W; Zhu J; Awasthi N; Sun X; Fung KM; He Y; Li M; Zhang C
Clin Cancer Res; 2019 Jun; 25(11):3317-3328. PubMed ID: 30796034
[TBL] [Abstract][Full Text] [Related]
38. Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer.
He S; Song W; Cui S; Li J; Jiang Y; Chen X; Peng L
Cell Oncol (Dordr); 2023 Dec; 46(6):1731-1746. PubMed ID: 37402945
[TBL] [Abstract][Full Text] [Related]
39. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
40. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
